The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 30, 2022
Filed:
Jul. 12, 2018
Bayer Pharma Aktiengesellschaft, Berlin, DE;
Bayer Aktiengesellschaft, Leverkusen, DE;
Deutsches Krebsforschungszentrum, Heidelberg, DE;
Jeffrey Stuart Mowat, Berlin, DE;
Bernd Buchmann, Hohen Neuendorf, DE;
Nuria Aiguabella Font, Berlin, DE;
Gabriele Leder, Berlin, DE;
Rafael Carretero, Heidelberg, DE;
Olaf Panknin, Berlin, DE;
Roland Neuhaus, Berlin, DE;
Robin Michael Meier, Wain, DE;
Sandra Berndt, Hohen Neuendorf, DE;
Kirstin Petersen, Berlin, DE;
Rienk Offringa, Heidelberg, DE;
Bayer Pharma Aktiengesellschaft, Berlin, DE;
Bayer Aktiengesellschaft, Leverkusen, DE;
Deutsches Krebsforschungszentrum, Heidelberg, DE;
Abstract
The present invention relates to protein-inhibitory substituted pyrrolopyridine derivatives of formula (I), in which A, X, R, R, R, R, R, Rand Rare as defined herein, to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, respectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients. The present invention further relates to the use, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of protein inhibitors in benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, in neurodegenerative disorders, in inflammatory disorders, in atherosclerotic disorders and in male fertility control.